Browse by Medical Category
Accepting New Patients
As Program Director for Breast Medical Oncology, Dr. Ellisen oversees an integrated and multidisciplinary unit focused on excellence in patient care and groundbreaking clinical and translational research.
Go To Programs
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
In the Ellisen Laboratory, scientists identify genetic abnormalities in tumor cells that are not present in normal tissues, study how the abnormalities influence the biology of cancer cells, and explore how their new discoveries can inform the selection of the most effective therapy for each patient. Key tumor cell pathways under investigation in the laboratory include p53, BRCA1/2, and mTOR. Dr. Ellisen is best known for his work on triple-negative breast cancer (TNBC), one of the most aggressive forms of the disease. His research has shown that a chemotherapy drug used to treat several other types of cancer - but rarely breast cancer - holds promise for TNBC patients. Dr. Ellisen now oversees clinical trials of this and many other promising new therapies in breast cancer.
View my most recent publications at PubMed
A study by researchers at three academic medical centers has shown that screening women with a suspected risk of hereditary breast or ovarian cancer for risk-associated genes other than BRCA1 and 2 provides information that can change clinical recommendations for patients and their family members.
coverage of study led by MGH investigator Leif Ellisen
The Massachusetts General Hospital Cancer Center is committed to advancing oncology care by tailoring treatment options to the individual cancer patient. The basic mission of the Translational Research Laboratory (TRL) is to provide rapid personalized genomic testing as an important component of routine care, thereby minimizing generalizations made in treatment decisions.
Back to Top